Clinical Trials Using Pralatrexate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Pralatrexate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-4 of 4
  • A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

    The purpose of this study is to evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed peripheral T-cell lymphoma (PTCL).
    Location: 4 locations

  • Pralatrexate and Romidepsin in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma

    This phase I / IIa trial studies the side effects and the best dose of pralatrexate and romidepsin and to see how well they work in treating patients with lymphoma or multiple myeloma that has come back after a period of improvement or does not respond to treatment. Pralatrexate may slow, stop, or decrease the growth of cancer cells by blocking how cells are made. Romidepsin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pralatrexate together with romidepsin may work better in treating patients with non-Hodgkin's lymphoma, Hodgkin's lymphoma, or multiple myeloma
    Location: 3 locations

  • Durvalumab, Pralatrexate, Romidepsin, and Oral Azacitidine in Treating Participants with Peripheral T-Cell Lymphoma

    This phase I and IIa trial studies the side effects and best dose of durvalumab, pralatrexate, romidepsin, and oral azacitidine, and to see how well they work in treating participants with peripheral T-cell lymphoma. Monoclonal antibodies, such as durvalumab, interfere with the ability of cancer cells to grow and spread. Pralatrexate is a chemotherapy drug that blocks how cells are made and therefore the growth of cancer cells can be slowed, stopped, or decreased. Romidepsin is another type of chemotherapy drug that helps stop the growth of cancer cells and can help kill cancer cells. Oral azacitidine prevents the body from making deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) that cells need to grow, which stops the growth of cancer cells and causes them to die. It is not yet known which combination of these drugs work best in treating participants with relapsed or refractory peripheral T-cell lymphoma.
    Location: Columbia University / Herbert Irving Cancer Center, New York, New York

  • Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies

    This study is to evaluate the effect of leucovorin in preventing or reducing Folotyn-related Grade 3 or higher oral mucositis.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington